{"id":109,"date":"2017-08-30T09:18:02","date_gmt":"2017-08-30T14:18:02","guid":{"rendered":"https:\/\/viceroyresearch.org\/?p=109"},"modified":"2020-12-16T14:48:17","modified_gmt":"2020-12-16T14:48:17","slug":"mitsubishi-tanabe-is-making-a-huge-mistake-why-we-believe-that-neuroderm-nasdaqndrm-is-a-lemon","status":"publish","type":"post","link":"https:\/\/viceroyresearch.org\/2017\/08\/30\/mitsubishi-tanabe-is-making-a-huge-mistake-why-we-believe-that-neuroderm-nasdaqndrm-is-a-lemon\/","title":{"rendered":"Neuroderm &#8211; Mitsubishi Tanabe is making a huge mistake: Why we believe that Neuroderm (NASDAQ:NDRM) is a lemon."},"content":{"rendered":"<p><a class=\"download-pdf-cta\" href=\"https:\/\/viceroyresearch.org\/wp-content\/uploads\/2017\/08\/final-ndrm-30-aug-2017-approved.pdf\">Neuroderm PDF Report Download<\/a><\/p>\n<p>We believe that Mitsubishi Tanabe and its board need to immediately put a hold on the Neuroderm acquisition. We don\u2019t know what representations have been made to Mitsubishi Tanabe by Neuroderm or others pushing this acquisition, but our research findings demonstrate the following:<\/p>\n<ul>\n<li>Neuroderm has misrepresented the <strong>SIZE<\/strong> of the market, the <strong>RELEVANCE <\/strong>of their clinical study, and the <strong>EFFECTIVENESS<\/strong> of their ND0612 pump-delivered drug.<\/li>\n<li>AbbVie\u2019s Duopa\/Duodopa pump is already <strong>ESTABLISHED<\/strong> in the market, has a <strong>SUBSTANTIALLY LOWER<\/strong> adverse effect rate, conducted its trials on an <strong>APPROPRIATE<\/strong> subject pool, and did not rely on <strong>SUPPLEMENTARY <\/strong>oral levodopa or entacapone, to boost its clinical trial results, unlike Neuroderm.<\/li>\n<li>Neuroderm claims the size of ND0612\u2019s target market across the USA and EU is ~350,000 patients. AbbVie\u2019s superior pump has targeted the <strong>SAME<\/strong> market, only capturing ~3,500 patients.<\/li>\n<li>The ND0612 drug is marketed towards <strong>ADVANCED<\/strong> stage Parkinson\u2019s sufferers, however the efficacy study for the drug was conducted on <strong>EARLY<\/strong> stage Parkinson\u2019s sufferers, which require substantially lower doses of the active drug component in order to be effective. We believe the FDA will closely review the stage 3 trials to ensure ND0612 is tested on an <strong>APPROPRIATE<\/strong> and <strong>RELEVANT<\/strong> subject pool.<\/li>\n<li>Neuroderm\u2019s ND0612 delivery pump is made up of <strong>GENERIC COMPONENTS<\/strong> and presents <strong>ZERO<\/strong> <strong>R&amp;D<\/strong> proprietary value.<\/li>\n<li>ND0612 is now only being tested for bioequivalence, not efficacy. While this may lead to a speedier FDA approved drug, Mitsubishi Tanabe is meant to be buying Neuroderm for its <strong>TECHNOLOGY<\/strong>. We see this concession as further evidence of Neuroderm\u2019s weak R&amp;D value, which Mitsubishi Tanabe thought it was buying with this acquisition.<\/li>\n<\/ul>\n<p>[scribd id=357603033 key=key-CfUrPUV4f9tyvPuiBG5m mode=scroll]<\/p>\n<p>&nbsp;<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Neuroderm PDF Report Download We believe that Mitsubishi Tanabe and its board need to immediately&#8230;<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_links_to":"","_links_to_target":""},"categories":[60],"tags":[],"table_tags":[],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v15.6.2 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Neuroderm - Mitsubishi Tanabe is making a huge mistake: Why we believe that Neuroderm (NASDAQ:NDRM) is a lemon. | Viceroy Research<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/viceroyresearch.org\/2017\/08\/30\/mitsubishi-tanabe-is-making-a-huge-mistake-why-we-believe-that-neuroderm-nasdaqndrm-is-a-lemon\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Neuroderm - Mitsubishi Tanabe is making a huge mistake: Why we believe that Neuroderm (NASDAQ:NDRM) is a lemon. | Viceroy Research\" \/>\n<meta property=\"og:description\" content=\"Neuroderm PDF Report Download We believe that Mitsubishi Tanabe and its board need to immediately...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/viceroyresearch.org\/2017\/08\/30\/mitsubishi-tanabe-is-making-a-huge-mistake-why-we-believe-that-neuroderm-nasdaqndrm-is-a-lemon\/\" \/>\n<meta property=\"og:site_name\" content=\"Viceroy Research\" \/>\n<meta property=\"article:published_time\" content=\"2017-08-30T14:18:02+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2020-12-16T14:48:17+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\">\n\t<meta name=\"twitter:data1\" content=\"1 minute\">\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Organization\",\"@id\":\"https:\/\/viceroyresearch.org\/#organization\",\"name\":\"Viceroy Research\",\"url\":\"https:\/\/viceroyresearch.org\/\",\"sameAs\":[],\"logo\":{\"@type\":\"ImageObject\",\"@id\":\"https:\/\/viceroyresearch.org\/#logo\",\"inLanguage\":\"en-US\",\"url\":\"https:\/\/viceroyresearch.org\/wp-content\/uploads\/2020\/12\/cropped-VT-Tulip.png\",\"width\":512,\"height\":512,\"caption\":\"Viceroy Research\"},\"image\":{\"@id\":\"https:\/\/viceroyresearch.org\/#logo\"}},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/viceroyresearch.org\/#website\",\"url\":\"https:\/\/viceroyresearch.org\/\",\"name\":\"Viceroy Research\",\"description\":\"A group of individuals that see the world differently.\",\"publisher\":{\"@id\":\"https:\/\/viceroyresearch.org\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":\"https:\/\/viceroyresearch.org\/?s={search_term_string}\",\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/viceroyresearch.org\/2017\/08\/30\/mitsubishi-tanabe-is-making-a-huge-mistake-why-we-believe-that-neuroderm-nasdaqndrm-is-a-lemon\/#webpage\",\"url\":\"https:\/\/viceroyresearch.org\/2017\/08\/30\/mitsubishi-tanabe-is-making-a-huge-mistake-why-we-believe-that-neuroderm-nasdaqndrm-is-a-lemon\/\",\"name\":\"Neuroderm - Mitsubishi Tanabe is making a huge mistake: Why we believe that Neuroderm (NASDAQ:NDRM) is a lemon. | Viceroy Research\",\"isPartOf\":{\"@id\":\"https:\/\/viceroyresearch.org\/#website\"},\"datePublished\":\"2017-08-30T14:18:02+00:00\",\"dateModified\":\"2020-12-16T14:48:17+00:00\",\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/viceroyresearch.org\/2017\/08\/30\/mitsubishi-tanabe-is-making-a-huge-mistake-why-we-believe-that-neuroderm-nasdaqndrm-is-a-lemon\/\"]}]},{\"@type\":\"Article\",\"@id\":\"https:\/\/viceroyresearch.org\/2017\/08\/30\/mitsubishi-tanabe-is-making-a-huge-mistake-why-we-believe-that-neuroderm-nasdaqndrm-is-a-lemon\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/viceroyresearch.org\/2017\/08\/30\/mitsubishi-tanabe-is-making-a-huge-mistake-why-we-believe-that-neuroderm-nasdaqndrm-is-a-lemon\/#webpage\"},\"author\":{\"@id\":\"https:\/\/viceroyresearch.org\/#\/schema\/person\/38e10fc7394949cc6e1f60bbc3ac77df\"},\"headline\":\"Neuroderm &#8211; Mitsubishi Tanabe is making a huge mistake: Why we believe that Neuroderm (NASDAQ:NDRM) is a lemon.\",\"datePublished\":\"2017-08-30T14:18:02+00:00\",\"dateModified\":\"2020-12-16T14:48:17+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/viceroyresearch.org\/2017\/08\/30\/mitsubishi-tanabe-is-making-a-huge-mistake-why-we-believe-that-neuroderm-nasdaqndrm-is-a-lemon\/#webpage\"},\"publisher\":{\"@id\":\"https:\/\/viceroyresearch.org\/#organization\"},\"articleSection\":\"Neuroderm NASDAQ:NDRM\",\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/viceroyresearch.org\/#\/schema\/person\/38e10fc7394949cc6e1f60bbc3ac77df\",\"name\":\"Viceroy Research\",\"image\":{\"@type\":\"ImageObject\",\"@id\":\"https:\/\/viceroyresearch.org\/#personlogo\",\"inLanguage\":\"en-US\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/0031e3f514f9d4a17ee5a39a058b5d7e?s=96&d=identicon&r=g\",\"caption\":\"Viceroy Research\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","_links":{"self":[{"href":"https:\/\/viceroyresearch.org\/wp-json\/wp\/v2\/posts\/109"}],"collection":[{"href":"https:\/\/viceroyresearch.org\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/viceroyresearch.org\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/viceroyresearch.org\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/viceroyresearch.org\/wp-json\/wp\/v2\/comments?post=109"}],"version-history":[{"count":2,"href":"https:\/\/viceroyresearch.org\/wp-json\/wp\/v2\/posts\/109\/revisions"}],"predecessor-version":[{"id":5009,"href":"https:\/\/viceroyresearch.org\/wp-json\/wp\/v2\/posts\/109\/revisions\/5009"}],"wp:attachment":[{"href":"https:\/\/viceroyresearch.org\/wp-json\/wp\/v2\/media?parent=109"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/viceroyresearch.org\/wp-json\/wp\/v2\/categories?post=109"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/viceroyresearch.org\/wp-json\/wp\/v2\/tags?post=109"},{"taxonomy":"table_tags","embeddable":true,"href":"https:\/\/viceroyresearch.org\/wp-json\/wp\/v2\/table_tags?post=109"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}